Novel therapies for malignant pleural mesothelioma
Despite the approval of bevacizumab, nivolumab, pembrolizumab and ipilimumab for unresectable pleural mesothelioma, no targeted therapies have been approved for treating the disease, and circulating biomarkers currently have limited diagnostic utility.
Pleural mesothelioma (PM) is a rare and aggressive cancer. Standard of care for unresectable disease consists of chemotherapy, vascular endothelial growth factor inhibition, immunotherapy, or combinations thereof. Despite recent therapeutic advances, validated diagnostic and prognostic biomarkers are lacking, and no targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) to date. Given the growing body of research investigating molecular alterations in PM, this review summarizes emerging diagnostic and prognostic biomarkers, discusses potentially targetable molecular alterations, and examines ongoing trials directed at targeting specific molecular mechanisms in this disease.
Pleural mesothelioma is a difficult to diagnose and treat cancer. Several biomarkers have been studied to help diagnose patients and monitor treatment response. One biomarker is approved but not commonly used in clinical practice. Pleural mesothelioma is also an aggressive cancer that is not surgically resectable for most patients who are diagnosed with it. Traditionally, chemotherapy, immunotherapy, or a combination of both is the standard of care for patients with advanced pleural mesothelioma. Many clinical trials have been performed to target mutations in mesothelioma, but none have been approved for treatment. In this article, we review potential circulating biomarkers and targeted therapy clinical trials that have occurred in pleural mesothelioma. We also discuss ongoing clinical trials and potential future targeted therapy treatment options for pleural mesothelioma.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma